Clinical Biotherapeutics

Clinical Biotherapeutic aspects including study design, drug-drug interactions, QT assessment, immunogenicity, comparability, special populations (hepatic and liver failure), PK and PD, regulatory expectations of PK and PD characterization, as well as reviewing factors which influence the ADME of Biotherapeutics. The objectives of early clinical development of therapeutic proteins are the same as for small molecules i.e. to investigate the molecule in a manner that will gain necessary knowledge about its tolerability safety pharmacokinetics (PK) and if possible pharmacodynamics (PD) effects in the most appropriate human populations while simultaneously protecting their safety. However, there are specific features of proteins that must be considered when designing clinical pharmacology studies.

  • Pharmacokinetics of therapeutic proteins
  • pharmacodynamics of therapeutic proteins
  • Toxicology of therapeutic proteins
  • Toxicology measures in therapeutic proteins
  • Clinical development of therapeutic proteins

Related Conference of Clinical Biotherapeutics

July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy
July 27-28, 2026

19th World Drug Delivery Summit

Paris, France
September 14-15, 2026

6th International Conference on Pharmaceutical Chemistry

Paris, France
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2026

5th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2026

5th World Congress on Precision and Personalized Medicine

Zurich, Switzerland

Clinical Biotherapeutics Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in